Literature DB >> 23419247

Treatment and mortality rate of bullous pemphigoid in China: a hospital-based study.

Li-Ming Zhang1, Jian Wu, Ting Xiao, Guang-Yu Jin, Jiu-Hong Li, Long Geng, Chun-Di He, Xing-Hua Gao, Hong-Duo Chen.   

Abstract

Bullous pemphigoid (BP) has been reported to be associated with significant morbidities and a considerable mortality rate. We retrospectively studied 94 patients with BP in a Chinese tertiary medical center between 2005 and 2010 to evaluate the treatment of BP and prognostic factors for the mortality of BP. Cerebrovascular diseases (42.55%) and hypertension (39.36%) were the most common pre-existing conditions. Cardiopathy, diabetes and psoriasis pre-existed in 24.47%, 22.34% and 5.32%, respectively. Eighty of all 94 patients were treated by systemic corticosteroid at prednisone 0.3 mg/kg to 1.5 mg/kg daily. Patients were followed up for a minimum of 1 year or until the time of death. The mean duration of follow-up was 32 months. Kaplan-Meier analysis showed a 1-year survival probability of 76.6% (standard error 4.4%), with a 95% confidence interval (68.04%, 85.16%). Multivariate analysis revealed that increased age, bedridden condition, presence of cerebrovascular diseases at diagnosis, pre-existing cardiopathy and low serum albumin level were associated with the elevated 1-year mortality rate of BP.

Entities:  

Keywords:  bullous pemphigoid; cerebrovascular disease; corticosteroid; mortality; prognosis

Mesh:

Substances:

Year:  2013        PMID: 23419247     DOI: 10.1684/ejd.2012.1906

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  6 in total

Review 1.  Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Authors:  Kyle T Amber; Dedee F Murrell; Enno Schmidt; Pascal Joly; Luca Borradori
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

2.  Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009.

Authors:  Katherine E Brick; Chad H Weaver; Christine M Lohse; Mark R Pittelkow; Julia S Lehman; Michael J Camilleri; Mustafa Al-Hashimi; Carilyn N Wieland
Journal:  J Am Acad Dermatol       Date:  2014-04-03       Impact factor: 11.527

3.  Prognostic factors for mortality in patients with bullous pemphigoid: a meta-analysis.

Authors:  Yi-Di Liu; Yan-Hong Wang; Yi-Cong Ye; Wen-Ling Zhao; Li Li
Journal:  Arch Dermatol Res       Date:  2017-03-19       Impact factor: 3.017

4.  Prognostic factors for mortality in bullous pemphigoid: A systematic review and meta-analysis.

Authors:  Xianxia Chen; Yaqiang Zhang; Zhicheng Luo; Yujuan Wu; Taoxiang Niu; Jiayuan Zheng; Yuanyuan Xie
Journal:  PLoS One       Date:  2022-04-15       Impact factor: 3.752

5.  Case Report: Omalizumab Successfully Treated Recalcitrant Bullous Pemphigoid in an Elderly Patient with Multiple Comorbidities.

Authors:  Jue Liu; Tingkai Xiang; Wei Wang; Zhangyu Bu
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-07-21

6.  Mortality and Comorbidity Profiles of Patients with Bullous Pemphigoid in Korea.

Authors:  Hyeon Woo Jeon; Sook Jung Yun; Seung-Chul Lee; Young Ho Won; Jee-Bum Lee
Journal:  Ann Dermatol       Date:  2017-12-26       Impact factor: 1.444

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.